Clinical Insights: August 11, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New…
Clinical Insights — March 2016 Issue
Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Briviact® (brivaracetam) February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset…
RxStrategies Clinical Insights — November 2015, Issue 2
Welcome to the second November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Ninlaro® (ixazomib) November 20, 2015 – The U.S. Food and Drug Administration approved ixazomib (Ninlaro®, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical…
RxStrategies Clinical Insights — November Issue 1
Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the…
HHS-OIG Criticizes 340B Drug Discount Program
Posted By Theresa C. Carnegie on February 11th, 2014Posted in Hospitals & Health Systems, Payors & PBMs, Pharma & Medical Devices, Pharmacies, State & Federal Audits, Investigations & Litigation Written by: Ellyn L. Sternfield I recently posted that 2014 is expected to be a year of major developments in the 340B Drug Discount Program, with HRSA receiving enhanced funding, stepping up audit activity, and drafting regulations in response to…
Hospitals look to reform 340b drug discount program
Jaimy Lee Posted: July 9, 2013 – 6:45 pm ET- Modern Health Safety net hospitals issued recommendations Tuesday for reforming the federal 340b drug discount program, which was designed to help clinics and hospitals serving the poor and uninsured but has become controversial because of alleged misuse by some hospitals.The recommendations included increased transparency of 340b prices and…
- « Previous
- 1
- 2